Role of soluble epoxide hydrolase in exacerbation of stroke by streptozotocin-induced type 1 diabetes mellitus

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 10, 2013, Pages 1650-1656

  Jouihan, Sari A ^a   Zuloaga, Kristen L ^a   Zhang, Wenri ^a   Shangraw, Robert E ^a   Krasnow, Stephanie M ^b   Marks, Daniel L ^b   Alkayed, Nabil J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

diabetes mellitus; EPHX2; hyperglycemia; streptozotocin; t AUCB

Indexed keywords

EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BRAIN BLOOD VESSEL; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN PERFUSION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME INHIBITION; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; BENZOATES; BLOOD GLUCOSE; CEREBRAL ANGIOGRAPHY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; EPOXIDE HYDROLASES; MALE; MICE; MICE, INBRED C57BL; OPTICAL IMAGING; REAL-TIME POLYMERASE CHAIN REACTION; STREPTOZOCIN; STROKE; UP-REGULATION; UREA;

EID: 84885018925     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.130     Document Type: Article

References (40)

1. Baird TA, Parsons MW, Barber PA, Butcher KS, Desmond PM, Tress BM et al. The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. J Clin Neurosci 2002; 9: 618-626. (Pubitemid 35364730)
2. Bruno A, Liebeskind D, Hao Q, Raychev R. Diabetes mellitus, acute hyperglycemia, and ischemic stroke. Curr Treat Opt Neurol 2010; 12: 492-503.
3. Pulsinelli WA, Levy DE, Sigsbee B, Scherer P, Plum F. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am J Med 1983; 74: 540-544. (Pubitemid 13125970)
4. Kostulas N, Markaki I, Cansu H, Masterman T, Kostulas V. Hyperglycaemia in acute ischaemic stroke is associated with an increased 5-year mortality. Age Ageing 2009; 38: 590-594.
5. Stead LG, Gilmore RM, Bellolio MF, Mishra S, Bhagra A, Vaidyanathan L et al. Hyperglycemia as an independent predictor of worse outcome in non-diabetic patients presenting with acute ischemic stroke. Neurocrit Care 2009; 10: 181-186.
6. Woo J, Lam CW, Kay R, Wong AH, Teoh R, Nicholls MG. The influence of hyperglycemia and diabetes mellitus on immediate and 3-month morbidity and mortality after acute stroke. Arch Neurol 1990; 47: 1174-1177. (Pubitemid 20380994)
7. Baird TA, Parsons MW, Phanh T, Butcher KS, Desmond PM, Tress BM et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 2003; 34: 2208-2214. (Pubitemid 37099838)
8. Fuentes B, Ortega-Casarrubios MA, Sanjose B, Castillo J, Leira R, Serena J et al. Persistent hyperglycemia 4155 mg/dl in acute ischemic stroke patients: How well are we correcting it?: Implications for outcome. Stroke 2010; 41: 2362-2365.
9. MacDougall NJ, Muir KW. Hyperglycaemia and infarct size in animal models of middle cerebral artery occlusion: Systematic review and meta-analysis. J Cereb Blood Flow Metab 2011; 31: 807-818.
10. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-1367.
11. Gerstein HC, Miller ME, Byington RP, Goff Jr. DC, Bigger JT, Buse JB et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. (Pubitemid 351831356)
12. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297.
13. Gray CS, Hildreth AJ, Sandercock PA, O'Connell JE, Johnston DE, Cartlidge NE et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: The UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 2007; 6: 397-406. (Pubitemid 46551852)
14. Iliff JJ, Alkayed NJ. Soluble epoxide hydrolase inhibition: targeting multiple mechanisms of ischemic brain injury with a single agent. Future Neurol 2009; 4: 179-199.
15. Iliff JJ, Jia J, Nelson J, Goyagi T, Klaus J, Alkayed NJ. Epoxyeicosanoid signaling in CNS function and disease. Prostaglandins Other Lipid Mediat 2010; 91: 68-84.
16. Liu JY, Tsai HJ, Hwang SH, Jones PD, Morisseau C, Hammock BD. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol 2009; 156: 284-296.
17. Zhang W, Iliff JJ, Campbell CJ, Wang RK, Hurn PD, Alkayed NJ. Role of soluble epoxide hydrolase in the sex-specific vascular response to cerebral ischemia. J Cereb Blood Flow Metab 2009; 29: 1475-1481.
18. Zhang W, Koerner IP, Noppens R, Grafe M, Tsai H-J, Morisseau C et al. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 2007; 27: 1931-1940. (Pubitemid 350129162)
19. Corenblum MJ, Wise VE, Georgi K, Hammock BD, Doris PA, Fornage M. Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat. Hypertension 2008; 51: 567-573. (Pubitemid 351156449)
20. Iliff JJ, Fairbanks SL, Balkowiec A, Alkayed NJ. Epoxyeicosatrienoic acids are endogenous regulators of vasoactive neuropeptide release from trigeminal ganglion neurons. J Neurochem 2010; 115: 1530-1542.
21. Fulton D, Falck JR, McGiff JC, Carroll MA, Quilley J. A method for the determination of 5,6-eet using the lactone as an intermediate in the formation of the diol. J Lipid Res 1998; 39: 1713-1721. (Pubitemid 28377937)
22. Whisnant JP, Wiebers DO, O'Fallon WM, Sicks JD, Frye RL. A population-based model of risk factors for ischemic stroke: Rochester, minnesota. Neurology 1996; 47: 1420-1428. (Pubitemid 26422530)
23. Spencer EA, Pirie KL, Stevens RJ, Beral V, Brown A, Liu B et al. Diabetes and modifiable risk factors for cardiovascular disease: the prospective million women study. Eur J Epidemiol 2008; 23: 793-799.
24. Marowsky A, Burgener J, Falck JR, Fritschy JM, Arand M. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. Neuroscience 2009; 163: 646-661.
25. Sura P, Sura R, Enayetallah AE, Grant DF. Distribution and expression of soluble epoxide hydrolase in human brain. J Histochem Cytochem 2008; 56: 551-559. (Pubitemid 351702299)
26. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with doca-salt hypertension. Am J Physiol Renal Physiol 2009; 297: F740-F748.
27. Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, Iliff J et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am J Physiol Heart Circ Physiol 2008; 295: H2128-H2134.
28. Chaudhary KR, Abukhashim M, Hwang SH, Hammock BD, Seubert JM. Inhibition of soluble epoxide hydrolase by trans-4-[4-(3-adamantan-1-yl-ureido)- cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury. J Cardiovasc Pharmacol 2010; 55: 67-73.
29. Luo P, Chang HH, Zhou Y, Zhang S, Hwang SH, Morisseau C et al. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther 2010; 334: 430-438.
30. Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai H-J et al. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol 2009; 174: 2086-2095.
31. Koerner IP, Zhang W, Cheng J, Parker S, Hurn PD, Alkayed NJ. Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia. Front Biosci 2008; 13: 2833-2841. (Pubitemid 351589201)
32. Zhang W, Otsuka T, Sugo N, Ardeshiri A, Alhadid YK, Iliff JJ et al. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke 2008; 39: 2073-2078.
33. Heizer ML, McKinney JS, Ellis EF. 14,15-epoxyeicosatrienoic acid inhibits platelet aggregation in mouse cerebral arterioles. Stroke 1991; 22: 1389-1393.
34. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 2007; 292: C996-1012. (Pubitemid 46442641)
35. Yang B, Graham L, Dikalov S, Mason RP, Falck JR, Liao JK et al. Overexpression of cytochrome p450 cyp2j2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 2001; 60: 310-320. (Pubitemid 32678296)
36. Merkel MJ, Liu L, Cao Z, Packwood W, Young J, Alkayed NJ et al. Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of stat3 signaling. Am J Physiol Heart Circ Physiol 2010; 298: H679-H687.
37. Thomas H, Schladt L, Knehr M, Oesch F. Effect of diabetes and starvation on the activity of rat liver epoxide hydrolases, glutathione s-transferases and peroxisomal beta-oxidation. Biochem Pharmacol 1989; 38: 4291-4297. (Pubitemid 20009029)
38. Oguro A, Fujita N, Imaoka S. Regulation of soluble epoxide hydrolase (sEH) in mice with diabetes: high glucose suppresses sEH expression. Drug Metab Pharmacokinet 2009; 24: 438-445.
39. Luo P, Zhou Y, Chang HH, Zhang J, Seki T, Wang CY et al. Glomerular 20-hete, eets, and tgf-beta1 in diabetic nephropathy. Am J Physiol Renal Physiol 2009; 296: F556-F563.
40. Koerner IP, Jacks R, DeBarber AE, Koop D, Mao P, Grant DF et al. Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. J Neurosci 2007; 27: 4642-4649. (Pubitemid 46663588)